𝔖 Bobbio Scriptorium
✦   LIBER   ✦

A randomised double-blind placebo-controlled crossover add-on trial of lamotrigine in patients with treatment-resistant partial seizures

✍ Scribed by P. Loiseau; A.W.C. Yuen; B. Duché; T. Ménager; M.C. Arné-Bès

Publisher
Elsevier Science
Year
1990
Tongue
English
Weight
874 KB
Volume
7
Category
Article
ISSN
0920-1211

No coin nor oath required. For personal study only.

✦ Synopsis

Efficacy and safety of lamotrigine (LTG) as add-on therapy was assessed in a randomised double-blind placebo-controlled trial of this drug in 23 adult patients with refractory partial seizures. Fifteen patients showed an improvement on LTG treatment, with a greater than 50% decrease in total seizure count in 7 patients. Fourteen patients experienced fewer simple and complex partial seizures, with 8 patients benefitting by more than a 50% decrease in seizure frequency. The drug was well tolerated over the 2 month treatment period. The plasma concentration of concomitant antiepileptic drugs remained unchanged. No haematological or chemical abnormalities were noted.

📜 SIMILAR VOLUMES

Mirtazapine add-on therapy in the treatm
Mirtazapine add-on therapy in the treatment of schizophrenia with atypical antipsychotics: a double-blind, randomised, placebo-controlled clinical trial
✍ Michael Berk; Clarissa S. Gama; Suresh Sundram; Harry Hustig; Les Koopowitz; Rus 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 78 KB 👁 1 views

## Abstract ## Objective Schizophrenia is a multifaceted illness with positive, negative and cognitive symptom domains. Standard treatments often focus on positive symptoms and may not adequately relieve other symptoms. Previous studies have suggested a role for mirtazapine in schizophrenia, parti

A double-blind, placebo-controlled evalu
A double-blind, placebo-controlled evaluation of the efficacy and safety of loreclezole as add-on therapy in patients with uncontrolled partial seizures
✍ T Rentmeester; A Janssen; J Hulsman; F Scholtes; B van der Kleij; J Overweg; J M 📂 Article 📅 1991 🏛 Elsevier Science 🌐 English ⚖ 655 KB

Sixty-two patients with uncontrolled partial seizures participated in a 12-week, double-blind, placebo-controlled add-on-trial. Thirty-two patients received loreclezole and 30 a placebo as add-on therapy. Loreclezole was targeted at a plasma level of 1-2 mg/l. In spite of an antiepileptic therapy, u

A randomized, double-blind, placebo-cont
A randomized, double-blind, placebo-controlled trial of safinamide as add-on therapy in early Parkinson's disease patients
✍ Fabrizio Stocchi; Rupam Borgohain; Marco Onofrj; Anthony H.V. Schapira; Mohit Bh 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 446 KB 👁 2 views

## Abstract Safinamide is an α‐aminoamide with both dopaminergic and nondopaminergic mechanisms of action evaluated as an add‐on to dopamine agonist (DA) therapy in early‐stage PD. In this 24‐week, double‐blind study, patients with early PD receiving a stable dose of a single DA were randomized to